Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01910129
Registration number
NCT01910129
Ethics application status
Date submitted
15/07/2013
Date registered
29/07/2013
Date last updated
23/04/2019
Titles & IDs
Public title
Neurostimulation to the Vagus Nerve for the Reduction in Frequency of Seizures Associated With Epilepsy
Query!
Scientific title
A Randomized, Multi-center, Double-blind, Parallel, Crossover Study of a Non-invasive Neurostimulation to the Vagus Nerve With the gammaCore Device for the Reduction in Frequency of Seizures Associated With Epilepsy.
Query!
Secondary ID [1]
0
0
173/2013
Query!
Secondary ID [2]
0
0
E-AU-01
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Seizure
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Epilepsy
Query!
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Devices - gammaCore
Active Comparator: gammaCore - Active stimulation treatment
Placebo Comparator: sham gammaCore - Inactive stimulation treatment
Treatment: Devices: gammaCore
vagal verve stimulation 3 times a day 8 hours apart
Query!
Intervention code [1]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Frequency of Seizures
Query!
Assessment method [1]
0
0
The seizure frequency was collected in the subject diary throughout Intervention 1/Phase 2 (8 weeks) and Intervention 2/Phase 3 (8 weeks).
Query!
Timepoint [1]
0
0
16 weeks
Query!
Secondary outcome [1]
0
0
Duration of Seizure
Query!
Assessment method [1]
0
0
Duration of seizure was recorded by the subject in the subject diary throughout Intervention 1/Phase 2 (8 weeks) and Intervention 2/Phase 3 (8 weeks).
Query!
Timepoint [1]
0
0
16 weeks
Query!
Secondary outcome [2]
0
0
Severity of Seizure
Query!
Assessment method [2]
0
0
The Seizure Severity Questionnaire (SSQ) is a self-reported assessment tool, which categorizes seizures into three phases: warning, ictal activity and postictal recovery. The recovery phase is subdivided into three components (cognitive, emotional and physical aspects of recovery), each of which is rated for frequency, severity and bothersome. Overall assessment of seizure severity is measured with the last two items.
Items are positively scored from a scale of 1-7, with lower scores representing a better status. 1 = none, never or mild and 7 = extremely frequent, severe or high.
The severity was reported for seizures occuring throughout Intervention 1/Phase 2 (8 weeks) and Intervention 2/Phase 3 (8 weeks).
Query!
Timepoint [2]
0
0
16 weeks
Query!
Secondary outcome [3]
0
0
Type of Adverse Events
Query!
Assessment method [3]
0
0
Type of adverse events were split in to Adverse Events, Adverse Device Effects and Serious Adverse Events. Adverse events were reported throughout Intervention 1/Phase 2 (8 weeks) and Intervention 2/Phase 3 (8 weeks).
For frequency see the Adverse Event Table.
Query!
Timepoint [3]
0
0
16 weeks
Query!
Secondary outcome [4]
0
0
Number of Seizure Free Days
Query!
Assessment method [4]
0
0
The number of seizure-free days was collected from the subjects' diary. The total number of days observed days for each phase and the total number of seizure free days for each phase are presented for the course of the study throughout Intervention 1/Phase 2 (8 weeks) and Intervention 2/Phase 3 (8 weeks).
Query!
Timepoint [4]
0
0
16 weeks
Query!
Secondary outcome [5]
0
0
Quality of Life in Epilepsy
Query!
Assessment method [5]
0
0
The Quality of Life in Epilepsy-31 (QOLIE-31) instrument is a self- administered questionnaire. It includes seven subscales: Overall Quality of Life, Seizure Worry, Emotional Well-Being, Energy/Fatigue, Cognitive, Medication Effects, and Social Function. Questions 1-30 can yield seven individual scores (per subtest) and a total (composite) score. Higher scores indicate better QOL with values ranging from 1 to 100.
Question 31 is a subjective assessment of one's general health condition.Higher scores indicate a better-reported general health condition with the range being 1-10.
Scores are presented at end of Intervention 1/Phase 2 (8 weeks) and at the end of Intervention 2/Phase 3 (8 weeks).
Query!
Timepoint [5]
0
0
16 weeks
Query!
Eligibility
Key inclusion criteria
1. The patient is diagnosed with epilepsy with; primary generalized tonic-clonic or
partial complex or simple complex or focal onset seizures, with or without secondary
generalization.
2. The patient's present antiepileptic drug (AED) therapy is ineffective or intolerable
3. The patient is receiving a stable dose of up to 2 oral AED medication(s) and is not
expected to have any change in his/her baseline AED treatment during the treatment
period.
4. The patient is having more than 2 recordable seizures a month.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
70
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. The patient has had status epilepticus within the last six months.
2. The patient has had epilepsy surgery or a VNS implant.
3. The patient has had a history or presence of seizures occurring only in clusters (too
frequently or indistinctly separated to be reliably counted).
4. The patient has had 4 weeks continuous seizure freedom last 2 months.
5. The patient has psychogenic non-epileptic seizures (PNES) seizures.
6. The patient has a concomitant progressive CNS disease including progressive myoclonus
epilepsy.
7. The patient has a significant history of cardiac, renal, neurologic (other than
epilepsy), psychiatric, oncologic, endocrinologic, metabolic, or hepatic disease,
which would adversely affect their participation in this study.
8. The patient has had an episode of status epilepticus within 4 weeks of Screening.
10. Has a lesion (including lymphadenopathy), dysaesthesia, previous surgery or abnormal
anatomy at the GammaCore treatment site.
11. Has known or suspected severe atherosclerotic cardiovascular disease, severe carotid
artery disease (e.g. bruits or history of TIA or CVA), congestive heart failure (CHF),
known severe coronary artery disease or recent myocardial infarction.
12. Has an abnormal baseline ECG (e.g. second and third degree heart block, atrial
fibrillation, atrial flutter, recent history of ventricular tachycardia or ventricular
fibrillation, or clinically significant premature ventricular contraction).
13. Has had a previous bilateral, right, or left cervical vagotomy. 14. Has uncontrolled
high blood pressure. 15. Is currently implanted with an electrical and/or neurostimulator
device, including but not limited to cardiac pacemaker or defibrillator, vagal
neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or
cochlear implant.
16. Has a history of carotid endarterectomy or vascular neck surgery on the right side.
17. Has been implanted with metal cervical spine hardware or has a metallic implant near
the GammaCore stimulation site.
18. Has a recent or repeated history of syncope. 19. Has a known history or suspicion of
substance abuse or addiction. 20. In the opinion of the investigator/research staff the
subject is incapable of operating the GammaCore device as intended and performing the data
collection procedures.
21. Is pregnant, nursing, thinking of becoming pregnant in the next 9 months, or of
childbearing years and is unwilling to use an accepted form of birth control.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/07/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/10/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
13
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Southern Neurology - Kogarah
Query!
Recruitment hospital [2]
0
0
Strategic Health Evaluators - Sydney
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
2067 - Sydney
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
ElectroCore INC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to see the effects of non-invasive vagal nerve stimulation for
the reduction in frequency of seizure associated with epilepsy in subjects 18 or older.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01910129
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Roy Beran, Professor
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01910129
Download to PDF